CMP Pharma and Kiel Laboratories Sign Development Agreement

CMP Pharma and Kiel Laboratories have signed an agreement to develop, seek regulatory approval, and commercialize two new prescription drugs.

The first drugs will be directed at the general population with special emphasis on the geriatric market, followed by a product to be directed at the pediatric market.

While both drugs already exist as FDA approved solid dosage forms, CMP will be filing NDAs to obtain approval for an alternate liquid dosage form.

Commenting on the agreement, Gerald Sakowski, CEO of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician, and the pharmacist.”

RELATED ARTICLES

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

Companies are keen to use miniature chemical reactors to make pharmaceuticals and fine chemicals, but are discouraged by their tendency to clog up. Researchers at KU Leuven have now devised an elegant way of using sound waves to keep the chemicals flowing.